Feline Vaccines Market Report 2026

Feline Vaccines Market Overview

• Feline Vaccines market size has reached to $1.77 billion in 2025 • Expected to grow to $2.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Surge In Pet Cat Population Fueling The Growth Of The Market Due To Rising Need For Preventive Veterinary Healthcare • Market Trend: Advanced Feline Vaccine Enhances Immunity With Low-Volume Dose • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Feline Vaccines Market?

Feline vaccines are biological preparations designed to stimulate a cat’s immune system to recognize and defend against specific infectious diseases. They work by introducing harmless antigens or weakened pathogens that help the body build immunity without causing illness. These vaccines play a crucial role in preventing severe conditions and reducing the spread of contagious diseases among feline populations. The main vaccine types of the feline vaccines include inactivated (killed) vaccines, live attenuated vaccines, and recombinant vaccines. Inactivated (killed) vaccines are composed of virus particles that have been rendered non-infectious while still eliciting an immune response, offering safety and stability for immunizing cats against multiple viral diseases. Different disease types include feline panleukopenia virus (FPV), feline calicivirus (FCV), feline herpesvirus type 1 (FHV-1), feline leukemia virus (FeLV), rabies, and feline immunodeficiency virus (FIV). Multiple technologies include live attenuated, inactivated, recombinant DNA, subunit, and toxoid-based approaches. Various routes of administration are injectable vaccines, intranasal vaccines, and oral vaccines, and they are used by several end-users such as veterinary hospitals, veterinary clinics, and animal research institutes.

What Is The Feline Vaccines Market Growth Forecast?

The feline vaccines market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing demand for advanced feline immunization, growing focus on preventive veterinary healthcare, rising adoption of combination vaccines, expanding investment in companion animal biotechnology, and increasing emphasis on early-life vaccination. Major trends in the forecast period include technology-driven vaccine innovations, advancements in recombinant and dna vaccine platforms, developments in adjuvant and antigen delivery systems, rising research and development in feline immunology, and innovation in needle-free and intranasal vaccination methods.

What Is The Driver Of The Feline Vaccines Market?

The growing pet cat population is expected to propel the growth of the feline vaccines market going forward. Pet cat population refers to the increasing number of domesticated cats owned by households for companionship, emotional support, and recreational purposes. The rise in the pet cat population is due to increasing pet adoption rates with the growing recognition of the mental and emotional benefits associated with pet ownership. Feline vaccines help reduce the prevalence of infectious diseases in cats by providing immunity against conditions such as feline leukemia virus (FeLV), feline panleukopenia, herpesvirus, and calicivirus, thereby extending lifespan and improving overall feline health. For instance, in June 2025, according to the American Pet Products Association (APPA), a US-based trade association, cat ownership rose by 23 percent in 2024 with households increasing from 40 million in 2023 to 49 million in 2024. Therefore, the growing pet cat population is driving the growth of the feline vaccines industry.

Key Players In The Global Feline Vaccines Market

Major companies operating in the feline vaccines market are Merck & Co. Inc., Boehringer Ingelheim Animal Health GmbH, Zoetis Inc., Intas Pharmaceuticals Ltd., Elanco Animal Health Incorporated, Ceva Santé Animale S.A., Virbac SA, Neogen Corporation, Laboratorios HIPRA S.A., Vetoquinol SA, Indian Immunologicals Limited, Jinyu Bio-Technology Co. Ltd., Ourofino Animal Health S.A., Biogénesis Bagó S.A., Biovet Private Limited, Hester Biosciences Limited, Biovet S.A., Durvet Inc., China Animal Husbandry Group Co. Ltd., Biopharma Laboratory, Kyoto Biken Laboratories Inc., Nisseiken Co. Ltd., Liaoning Yikang Biological Co. Ltd., Torigen Pharmaceuticals Inc., Bioveta a.s.

Global Feline Vaccines Market Trends and Insights

Major companies operating in the feline vaccines market are focusing on developing advanced products, such as recombinant vector vaccines, to boost efficacy, enhance safety, and provide broader protection. Recombinant vector vaccines refer to advanced immunizations that use a harmless virus to deliver specific antigens, stimulating a strong and targeted immune response against the target pathogen. For instance, in September 2024, MSD Animal Health, a US-based global animal health company, received USDA approval for Nobivac NXT FeLV, a feline leukemia virus vaccine leveraging its RNA-particle technology platform. It is a next-generation, non-adjuvanted recombinant canarypox vector vaccine for feline leukemia virus (FeLV). The vaccine features a patented technology designed to induce robust cell-mediated and humoral immunity, providing enhanced protection against FeLV infection and associated diseases. It also incorporates a low-volume, subcutaneous dose and is indicated for healthy cats 8 weeks of age or older, aiming to improve safety profiles, ease of administration, and compliance in veterinary practices.

What Are Latest Mergers And Acquisitions In The Feline Vaccines Market?

In September 2024, Boehringer Ingelheim International GmbH, a Germany-based biopharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. Through this acquisition, Boehringer Ingelheim aims to integrate Saiba’s virus-like-particle vaccine technology to enhance its companion animal health portfolio, targeting chronic diseases in cats and dogs. Saiba Animal Health AG is a Switzerland-based company developing virus-like-particle (VLP)-based vaccines and therapeutics for cats and other companion animals.

What Defines the Feline Vaccines Market?

The feline vaccines market consists of sales of feline viral rhinotracheitis vaccines, feline calicivirus vaccines, feline panleukopenia vaccines, feline leukemia virus vaccines, and combination multivalent feline vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Feline Vaccines Market Report 2026?

The feline vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the feline vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.